1. 2000
2. Published

   The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies

   Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Jan 2000, In: Value in Health. 3, 5, p. 373

   Research output: Contribution to journal › Article › peer-review

3. Published

   Pragmatic trials - design features and implications for clinical decision making

   Hughes, D., Urdahl, H., Hughes, D. A. & Freemantle, N., 1 Aug 2000.

   Research output: Contribution to conference › Paper

4. Published

   The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies

   Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Nov 2000.

   Research output: Contribution to conference › Paper

5. 2001
6. Published

   A review of economic models for second-line chemotherapy in the management of advanced, metastatic breast cancer.

   Hughes, D. & Hughes, D. A., 1 Jan 2001, 2001 ed. Unknown.

   Research output: Book/Report › Commissioned report

7. Published

   Accounting for non-compliance in pharmacoeconomic evaluations.

   Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Jan 2001, In: Pharmacoeconomics. 19, 12, p. 1185-1197

   Research output: Contribution to journal › Article › peer-review

8. Published

   Economic evaluations during early (Phase II) drug development: A role for clinical trial simulations.

   Hughes, D., Hughes, D. A. & Walley, T., 1 Jan 2001, In: Pharmacoeconomics. 19, 11, p. 1069-1077

   Research output: Contribution to journal › Article › peer-review

9. Published

   Pharmacokinetic-Pharmacodynamic modelling of Lapdap (CPG-DDS) combination.

   Hughes, D., Hughes, D. A., Watkins, B. & Winstanley, P., 1 Jan 2001, 2001 ed. Unknown.

   Research output: Book/Report › Commissioned report

10. Published

    The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies.

    Hughes, D. & Hughes, D. A., 1 Jan 2001, 2001 ed. Unknown.

    Research output: Book/Report › Commissioned report

11. Published

    Impact of non-compliance on the cost-effectiveness of statin therapy

    Hughes, D., Hughes, D. A. & Bagust, A., 1 Sept 2001, In: Value in Health. 4, 6, p. 489

    Research output: Contribution to journal › Article › peer-review

12. Published

    Pharmacometric analysis of duration of drug action: implications for improved forgiveness to medication non-compliance

    Hughes, D., Hughes, D. A. & Walley, T., 1 Sept 2001.

    Research output: Contribution to conference › Paper

13. Published

    Patient compliance and pharmacoeconomics

    Hughes, D. & Hughes, D. A., 1 Oct 2001.

    Research output: Contribution to conference › Paper

14. Published

    The impact of non-compliance on the cost-effectiveness of pharmaceuticals: A review of the literature.

    Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Oct 2001, In: Health Economics. 10, 7, p. 601-615

    Research output: Contribution to journal › Article › peer-review

15. Published

    Impact of non-compliance on the clinical and cost-effectiveness of statins

    Hughes, D. & Hughes, D. A., 1 Nov 2001.

    Research output: Contribution to conference › Paper

16. 2002
17. Published

    Impact of non-compliance on the therapeutic coverage of oxybutynin – comparison of once- and twice-daily oral formulations.

    Hughes, D. & Hughes, D. A., 1 Jan 2002, 2002 ed. Unknown.

    Research output: Book/Report › Commissioned report

18. Published

    Impact of non-compliance on the therapeutic coverage of risperidone – comparison of long acting injectible with oral formulations.

    Hughes, D. & Hughes, D. A., 1 Jan 2002, 2002 ed. Unknown.

    Research output: Book/Report › Commissioned report

19. Published

    From efficacy to cost-effectiveness: accounting for non-compliance in pharmacoeconomics

    Hughes, D. & Hughes, D. A., 1 May 2002.

    Research output: Contribution to conference › Paper

20. Published

    Economic impact of poor compliance with pharmaceuticals.

    Hughes, D. & Hughes, D. A., 1 Aug 2002, In: Expert Review of Pharmacoeconomics and Outcomes Research. 2, 4, p. 327-335

    Research output: Contribution to journal › Article › peer-review

21. Published

    Accurate and practical dosing of African populations using a height, weight and age model designed for lapdap

    Hughes, D., Hughes, D. A. & Bagust, A., 1 Nov 2002.

    Research output: Contribution to conference › Paper

22. Published

    Economic evaluation during early (phase II) trials

    Hughes, D. & Hughes, D. A., 1 Nov 2002.

    Research output: Contribution to conference › Paper

23. Published

    Impact of non-compliance on the cost-effectiveness of pharmaceuticals

    Hughes, D. & Hughes, D. A., 1 Nov 2002.

    Research output: Contribution to conference › Paper

24. Published

    Patient compliance and pharmacoeconomics

    Hughes, D. & Hughes, D. A., 1 Nov 2002.

    Research output: Contribution to conference › Paper

25. Published

    The population pharmacokinetics of lapdap

    Hughes, D., Ward, S., Simpson, J., Aarons, L., Szwandt, S. & Hughes, D. A., 1 Nov 2002.

    Research output: Contribution to conference › Paper

26. 2003
27. Published

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D. & Hughes, D. A., 1 May 2003.

    Research output: Contribution to conference › Paper

28. Published

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D. & Hughes, D. A., 1 Jun 2003.

    Research output: Contribution to conference › Paper

29. Published

    Predicting "real world" effectiveness by integrating adherence with pharmacodynamic modelling.

    Hughes, D., Hughes, D. A. & Walley, T., 1 Jul 2003, In: Clinical Pharmacology and Therapeutics. 74, 1, p. 1-8

    Research output: Contribution to journal › Article › peer-review

30. Published

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Sept 2003.

    Research output: Contribution to conference › Paper

31. Published

    Modelling changes in first line antimalarial therapy

    Hughes, D. & Hughes, D. A., 1 Sept 2003.

    Research output: Contribution to conference › Paper

32. Published

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Nov 2003.

    Research output: Contribution to conference › Paper

33. Published

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Nov 2003, In: Value in Health. 6, 6, p. 749

    Research output: Contribution to journal › Article › peer-review

34. Published

    Cost-utility analysis of on demand rabeprazole and esomeprazole for symptomatic gastro oesophageal reflux disease

    Hughes, D., Hughes, D. A. & Dubois, D., 1 Nov 2003, In: Value in Health. 6, 6, p. 613

    Research output: Contribution to journal › Article › peer-review

35. Published

    Cost-utility analysis of on-demand rabeprazole and esomeprazole for non-erosive reflux disease

    Hughes, D. & Hughes, D. A., 1 Nov 2003.

    Research output: Contribution to conference › Paper

36. Published

    Cost-utility analysis of on-demand rabeprazole and esomeprazole for non-erosive reflux disease

    Hughes, D. & Hughes, D. A., 1 Nov 2003.

    Research output: Contribution to conference › Paper

37. Published

    Use of PK-PD modelling to predict the impact of non-compliance

    Hughes, D. & Hughes, D. A., 1 Nov 2003.

    Research output: Contribution to conference › Paper

38. Published

    Drug compliance and pharmaceconomics

    Hughes, D. & Hughes, D. A., 1 Dec 2003.

    Research output: Contribution to conference › Paper

39. 2004
40. Published

    Approaches to pharmacoeconomic analysis

    Hughes, D., Hughes, D. A., Walley, T. (ed.), Haycox, A. (ed.), Boland, A. (ed.) & Breckenridge, A. (ed.), 1 Jan 2004, Pharmacoeconomics. 2004 ed. Adis International, p. 101-126

    Research output: Chapter in Book/Report/Conference proceeding › Chapter

41. Published

    Clinical Pharmacology: Special safety considerations in drug development and pharmacovigilance.

    Hughes, D., Atuah, K. N., Hughes, D. A. & Pirmohamed, M., 1 Jan 2004, In: Drug Safety. 27, 8, p. 535-554

    Research output: Contribution to journal › Article › peer-review

42. Published

    Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence.

    Hughes, D., Hughes, D. A. & Dubois, D., 1 Jan 2004, In: Pharmacoeconomics. 22, 16, p. 1047-1059

    Research output: Contribution to journal › Article › peer-review

43. Published

    Internationalisation of cost-effectiveness model for on-demand use of proton pump inhibitors - Belgium.

    Hughes, D. & Hughes, D. A., 1 Jan 2004, 2004 ed. Unknown.

    Research output: Book/Report › Commissioned report

44. Published

    Modelling in health economics

    Hughes, D., Hughes, D. A., Walley, T. (ed.), Haycox, A. (ed.), Boland, A. (ed.) & Breckenridge, A. (ed.), 1 Jan 2004, Pharmacoeconomics. 2004 ed. Adis International, p. 141-154

    Research output: Chapter in Book/Report/Conference proceeding › Chapter

45. Published

    The future challenges

    Hughes, D., Hughes, D. A., Walley, T. (ed.), Haycox, A. (ed.), Boland, A. (ed.) & Breckenridge, A. (ed.), 1 Jan 2004, Pharmacoeconomics. 2004 ed. Adis International, p. 167-174

    Research output: Chapter in Book/Report/Conference proceeding › Chapter

46. Published

    Pharmacoeconomics in Wales: functions of the all Wales medicines strategy group

    Hughes, D. & Hughes, D. A., 1 Apr 2004.

    Research output: Contribution to conference › Paper

47. Published

    Pharmacoeconomics of pharmacogenetic testing: azathioprine

    Hughes, D., McAllister, R. & Hughes, D. A., 1 Apr 2004.

    Research output: Contribution to conference › Paper

48. Published

    Patient compliance and persistence with prescribed medication: Measurement and health economic impact

    Hughes, D., Koncz, T., Hughes, D. A., Cleemput, I. & Annemans, L., 1 May 2004.

    Research output: Contribution to conference › Paper

49. Published

    Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

    Hughes, D., Hughes, D. A., Vilar, F. J., Ward, C. C., Alfirevic, A., Park, B. K. & Pirmohamed, M., 1 Jun 2004, In: Pharmacogenetics. 14, 6, p. 335-342

    Research output: Contribution to journal › Article › peer-review

50. Published

    Introduction to pharmaeconomics

    Hughes, D. & Hughes, D. A., 1 Jul 2004.

    Research output: Contribution to conference › Paper

51. Published

    Pharmacoeconomic models that incorporate non-compliance

    Hughes, D. & Hughes, D. A., 1 Jul 2004.

    Research output: Contribution to conference › Paper

52. Published

    Pharmacoeconomics appraisals by the all Wales medicines strategy group

    Hughes, D. & Hughes, D. A., 1 Jul 2004.

    Research output: Contribution to conference › Paper

53. Published

    The difference between effectiveness and efficacy of antimalarial drugs in Kenya.

    Hughes, D., Amin, A. A., Hughes, D. A., Marsh, V., Abuya, T. O., Kokwaro, G. O., Winstanley, P. A., Ochala, S. A. & Snow, R. W., 1 Sept 2004, In: Tropical Medicine and International Health. 9, 9, p. 967-974

    Research output: Contribution to journal › Article › peer-review

54. Published

    Economic evaluation of on-demand maintenance therapy with proton pump inhibitors in patients with symptomatic gastroesophageal reflux disease - a Monte-Carlo analysis for Italy

    Hughes, D., Hughes, D. A., Marchetti, M. & Colombo, G., 1 Oct 2004.

    Research output: Contribution to conference › Paper

55. Published

    A single centre open phase IV study to evaluate the safety and tolerability of chlorproguanil-dapsone when dosed by defined height bands

    Hughes, D., Makanga, M., Winstanley, P. & Hughes, D. A., 1 Nov 2004.

    Research output: Contribution to conference › Paper

56. Published

    Cost minimization of on-demand maintenance therapy with proton pump inhibitors in nonerosive gastroesophageal reflux disease

    Hughes, D. & Hughes, D. A., 1 Nov 2004, In: Value in Health. 7, 6, p. 753

    Research output: Contribution to journal › Article › peer-review

57. Published

    From efficacy to effectiveness and cost-effectiveness: modelling possibilities

    Hughes, D. & Hughes, D. A., 1 Nov 2004.

    Research output: Contribution to conference › Paper

58. Published

    HLA-B*5701 and abacavir hypersensitivity - Reply.

    Hughes, D., Hughes, D. A., Park, B. K. & Pirmohamed, M., 1 Nov 2004, In: Pharmacogenetics. 14, 11, p. 784

    Research output: Contribution to journal › Article › peer-review

59. 2005
60. Published

    Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease.

    Hughes, D., Hughes, D. A., Bodger, K., Bytzer, P., De Herdt, D. & Dubois, D., 1 Jan 2005, In: Pharmacoeconomics. 23, 10, p. 1031-1041

    Research output: Contribution to journal › Article › peer-review

61. Published

    Improving Outcomes in Children and Young People with Cancer: Analysis of the Potential Economic Impact of the Guidance.

    Hughes, D., Linck, P., Tunnage, B., Hughes, D. A. & Edwards, R. T., 1 Jan 2005, 2005 ed. Unknown.

    Research output: Book/Report › Commissioned report

62. Published

    Internationalisation of cost-effectiveness model for on-demand use of proton pump inhibitors - Sweden.

    Hughes, D. & Hughes, D. A., 1 Jan 2005, 2005 ed. Unknown.

    Research output: Book/Report › Commissioned report

63. Published

    Welsh Health Economics Network (WHEN): Scoping Report.

    Hughes, D., Farr, A., O Ceilleachair, A., Cohen, D., Hughes, D. A. & Phillips, C., 1 Jan 2005, 2005 ed. Unknown.

    Research output: Book/Report › Commissioned report

64. Published

    Cost minimization of on-demand maintenance therapy with proton pump inhibitors in nonerosive gastroesophageal reflux disease.

    Hughes, D., Hughes, D. A., Marchetti, M. & Colombo, G., 1 Feb 2005, In: Expert Review of Pharmacoeconomics and Outcomes Research. 5, 1, p. 29-38

    Research output: Contribution to journal › Article › peer-review

65. Published

    Empirical analysis of the relationship between dose and duration of drug action

    Hughes, D. & Hughes, D. A., 1 Jun 2005.

    Research output: Contribution to conference › Paper

66. Published

    Pharmacokinetics, patient compliance and pharmaeconomics

    Hughes, D. & Hughes, D. A., 1 Jun 2005.

    Research output: Contribution to conference › Paper

67. Published

    Cisplatin plus vinorelbine or gemcitabine in patients with advanced non-small cell lung cancer: Pharmacoeconomic considerations.

    Hughes, D. & Hughes, D. A., 1 Jul 2005, In: European Journal of Cancer. 41, 11, p. 1655

    Research output: Contribution to journal › Article › peer-review

68. Published

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 1 Jul 2005.

    Research output: Contribution to conference › Paper

69. Published

    Drugs for exceptionally rare diseases: do they deserve special status for funding?

    Hughes, D., Tunnage, B. & Yeo, S. T., 1 Nov 2005, In: QJM - An International Journal of Medicine. 98, 11, p. 829-836

    Research output: Contribution to journal › Article › peer-review

70. Published

    Incorporating measures of compliance and persistence in pharmacoeconomic evaluations

    Hughes, D., Hughes, D. A. & Cowell, W., 1 Nov 2005.

    Research output: Contribution to conference › Paper

71. Published

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 1 Nov 2005.

    Research output: Contribution to conference › Paper

72. Published

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 1 Nov 2005.

    Research output: Contribution to conference › Paper

73. Published

    Trends and influences on use of antidiabetic drugs in England, 1992-2003.

    Walley, T., Hughes, D. & Kendall, H., 1 Nov 2005, In: Pharmacoepidemiology and Drug Safety. 14, 11, p. 769-773

    Research output: Contribution to journal › Article › peer-review

74. Published

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 11 Nov 2005, In: Value in Health. 8, 6, p. A192

    Research output: Contribution to journal › Article › peer-review

75. 2006
76. Published

    Beyond registration: measuring the public health potential of new treatments for Malaria in Africa.

    Hughes, D., Lang, T., Hughes, D. A., Kanyok, T., Kengeya-Kayondo, J., Marsh, V., Haaland, A., Pirmohamed, M. & Winstanley, P., 1 Jan 2006, In: Lancet Infectious Diseases. 6, 1, p. 46-52

    Research output: Contribution to journal › Article › peer-review

77. Published

    Health economic aspects of patient non-compliance

    Hughes, D., Hughes, D. A., Davies, M. (ed.) & Kermani, F. (ed.), 1 Jan 2006, Patient Compliance: Sweetening the Pill. 2006 ed. Gower Publishing, p. 23-40

    Research output: Chapter in Book/Report/Conference proceeding › Chapter

78. Published

    Improving Outcomes for People with Brain and Other CNS Tumours: Analysis of the Potential Economic Impact of the Guidance.

    Hughes, D., Linck, P., Priedane, E., Hughes, D. A. & Edwards, R. T., 1 Jan 2006, 2006 ed. Unknown.

    Research output: Book/Report › Commissioned report

79. Published

    Improving Outcomes for People with Sarcoma: Analysis of the Potential Economic Impact of the Guidance.

    Hughes, D., Linck, P., Hughes, D. A. & Edwards, R. T., 1 Jan 2006, 2006 ed. Unknown.

    Research output: Book/Report › Commissioned report

80. Published

    Less is more: Medicines that require less frequent administration improve adherence, but are they better?

    Hughes, D. & Hughes, D. A., 1 Jan 2006, In: Pharmacoeconomics. 24, 3, p. 211-213

    Research output: Contribution to journal › Article › peer-review

81. Published

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 1 Jan 2006.

    Research output: Contribution to conference › Paper

82. Published

    Rationing of drugs for rare diseases.

    Hughes, D. & Hughes, D. A., 1 Jan 2006, In: Pharmacoeconomics. 24, 4, p. 315-316

    Research output: Contribution to journal › Article › peer-review

83. Published

    Improving Outcomes for People with Skin Tumours including Melanoma: Analysis of the Potential Economic Impact of the Guidance.

    Hughes, D., Linck, P., Hughes, D. A. & Edwards, R. T., 21 Feb 2006, Unknown.

    Research output: Book/Report › Commissioned report

84. Published

    Eliciting patients' preferences using a discrete choice experiment questionnaire: the role played by qualitative data in questionnaire design

    Hughes, D., Longo, M., Hughes, D. A., Myles, S. & Lisles, C., 1 Mar 2006.

    Research output: Contribution to conference › Paper

85. Published

    Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone.

    Simpson, J. A., Hughes, D., Manyando, C., Bojang, K., Aarons, L., Winstanley, P., Edwards, G., Watkins, W. A. & Ward, S., 1 Mar 2006, In: British Journal of Clinical Pharmacology. 61, 3, p. 289-300

    Research output: Contribution to journal › Article › peer-review

86. Published

    Health and economic outcomes: Why compliance matters

    Hughes, D. & Hughes, D. A., 1 Apr 2006.

    Research output: Contribution to conference › Paper

87. Published

    Physchiatrist prescribing preferences and attitudes toward promotion

    Hughes, D., Menkes, D., Davies, R. & Hughes, D. A., 1 Apr 2006.

    Research output: Contribution to conference › Paper

88. Published

    Rationing of drugs for rare diseases

    Hughes, D. & Hughes, D. A., 1 Apr 2006.

    Research output: Contribution to conference › Paper

89. Published

    Back to basics: what is the relationship between dose and duration of drug action?

    Hughes, D. & Hughes, D. A., 1 May 2006.

    Research output: Contribution to conference › Paper

90. Published

    Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments

    Hughes, D. & Hughes, D. A., 1 May 2006.

    Research output: Contribution to conference › Paper

91. Published

    Orphan drugs revisited: author's response.

    Hughes, D. & Hughes, D. A., 1 May 2006, In: Quarterly Journal of Medicine. 99, 5, p. 350-351

    Research output: Contribution to journal › Article › peer-review

92. Published

    Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments - piloting a discrete choice experiment

    Hughes, D., Myles, S., Hughes, D. A., Longo, M. & Lisles, C., 1 Jun 2006.

    Research output: Contribution to conference › Paper

93. Published

    Prescription fee exemption research study

    Hughes, D., Myles, S., Hughes, D. A., Routledge, P. & Wales, D. F., 1 Jun 2006.

    Research output: Contribution to conference › Paper

94. Published

    Clinical and econnomic importance of completion of therapy in the treatment of LRTIs

    Hughes, D. & Hughes, D. A., 1 Sept 2006.

    Research output: Contribution to conference › Paper

95. Published

    Ultra-long acting pharmaceuticals: Do they result in better outcomes, and at an acceptable cost?

    Hughes, D. & Hughes, D. A., 1 Nov 2006.

    Research output: Contribution to conference › Paper

96. 2007
97. Published

    AWMSG criteria for appraising new medicines.

    Hughes, D. & Hughes, D. A., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

98. Published

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Jan 2007, In: Value in Health. 10, 3, p. A109

    Research output: Contribution to journal › Article › peer-review

99. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Emtricitabine/tenofovir DF (Truvada)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

100. Published

     All Wales Medicines Strategy Group Final Appraisal Report – Clofarabine (Evoltra)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

     Research output: Book/Report › Commissioned report

101. Published

     All Wales Medicines Strategy Group Final Appraisal Report – Co-careldopa intestinal gel (Duodopa).

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

     Research output: Book/Report › Commissioned report

102. Published

     All Wales Medicines Strategy Group Final Appraisal Report – Darunavir (Prezista)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

     Research output: Book/Report › Commissioned report

103. Published

     All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Chronic, accelerated or blast phase CML.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

     Research output: Book/Report › Commissioned report

104. Published

     All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Lymphoid blast CML and PH+ ALL.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

     Research output: Book/Report › Commissioned report

105. Published

     All Wales Medicines Strategy Group Final Appraisal Report – Dexrazoxane (Savene)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

     Research output: Book/Report › Commissioned report

106. Published

     All Wales Medicines Strategy Group Final Appraisal Report – Emtricitabine (Emtriva)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

     Research output: Book/Report › Commissioned report

107. Published

     All Wales Medicines Strategy Group Final Appraisal Report – Idursulfase (Elaprase)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

     Research output: Book/Report › Commissioned report

108. Published

     All Wales Medicines Strategy Group Final Appraisal Report – Parathyroid hormone (Preotact)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

     Research output: Book/Report › Commissioned report